Oral antiviral medications are FDA authorized for COVID-19. These medications work by interfering with the ability of the COVID-19 virus to replicate inside the body. This lowers the "viral load," which is the amount of virus doctors find in your body. This can help reduce the severity of COVID-19 symptoms and shorten the length of the illness.

This table is for informational purposes only. Treatments require a prescription and should be guided by a patient’s healthcare team.

### Paxlovid® (nirmatrelvir and ritonavir tablets)

**Important note:** Paxlovid may impair the efficacy and safety of certain cancer medications. It should be used with the guidance of your oncologist.

**Authorized for:** Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors)

Paxlovid treatment is not:
- For use in preventing COVID-19 infection
- Authorized for use longer than 5 consecutive days

**Ages:** Adults 18 years and older
Children 12 and up who weigh at least 88 pounds

**Activity against Omicron:** Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients

**Dosing/Timing:**
- Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset
- Three tablets (2 nirmatrelvir and 1 ritonavir) taken together twice daily for 5 days
- Can be taken with or without food

**Manufacturer:** Pfizer


### Lagevrio® (molnupiravir)

**Authorized for:** Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors)

Lagevrio treatment is not:
- For use in preventing COVID-19 infection
- Authorized for use longer than 5 consecutive days

**Ages:** Adults 18 years and older

**Activity against Omicron:** Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients

**Dosing/Timing:**
- Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset
- Four capsules taken every 12 hours for 5 days
- Can be taken with or without food

**Manufacturer:** Merck & Co., Inc.

To read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers, visit: https://www.merck.com/eua/molnupiravir-patient-fact-sheet-english.pdf

---

1. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid
3. Vangeel L et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern.

As of 1/18/2022